<DOC>
	<DOC>NCT00174824</DOC>
	<brief_summary>To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.</brief_summary>
	<brief_title>Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients</brief_title>
	<detailed_description>Randomized, open-label assignment of type 2 patients who are on a stable antidiabetic regimen to treatment with either insulin glargine or BID NPH human insulin, with baseline diabetic retinopathy of severity 53/&lt;53 on the ETDRS scale, for 5 years of followup. Outcomes measured by seven-field fundus photography at baseline, 1.5, 3,6,and 9 months, and annually.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus for at least 1 year treated with oral antidiabetic agents or insulin at stable doses for at least 3 months HbA1c between 6 and 12% inclusive baseline retinopathy severity not to exceed 53/&lt;53 on the ETDRS scale unlikely to require laser surgery or vitrectomy within upcoming year prior treatment with insulin glargine treatment with insulin analogs (eg insulin lispro or aspart) in the year prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Retinopathy</keyword>
</DOC>